Hidradenitis Suppurativa Treatment Market: Global Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Hidradenitis Suppurativa Treatment Market: By Clinical Stage (Hurley Stage 1, Hurley Stage 2, Hurley Stage 3) Drug Type (Biologics, Antibiotics, Hormonal therapy, Immune suppurativa drugs, Pain medications Others) Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

Hidradenitis Suppurativa Treatment Market size is valued at USD 721.9 million in 2021 and is expected to grow at a prominent growth rate 4.50% during the forecast period 2022 to 2028. The global market provides a detailed overview of the global Hidradenitis Suppurativa Treatment market, and that can be segmented by Clinical Stage, by Drug Type, by Distribution Channel. By Clinical Stage, the global Hidradenitis Suppurativa Treatment market has been segmented into Hurley Stage 1, Hurley Stage 2, Hurley Stage 3. The hurley stage 1 Suppurativa Treatment segment is likely to be the largest and fastest-growing segment in terms of type. Based on Drug type, the global Hidradenitis Suppurativa Treatment market is segmented into Biologics, Antibiotics, Hormonal therapy, Immune suppurativa drugs, Pain medications, Others. Among these, the biologics segment is expected to have the fastest-growing market during the forecast period 2022-2028. Based on distribution channel, the global Hidradenitis Suppurativa Treatment market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies. The Hospital Pharmacies segment accounts for the largest share in 2021. Retail segment is the second-largest share during the forecast period 2022-2028.

Key Developments:

In Feb 2019, InflaRx N.V., which is recognized for creating novel therapies to treat inflammatory diseases, recently released new clinical results including the use of IFX-1 in patients with moderate to severe Hidradenitis Suppurativa.

In March 2022, MoonLake began testing nanobody, sonelokimab in a Phase II clinical trial to treat moderate-to-severe hidradenitis suppurativa (HS). By blocking the IL-17A/A, IL-17A/F, and IL-17F/F dimers that induce inflammation in the body, sonelokimab may be able to cure inflammatory conditions.

Hidradenitis Suppurativa Treatment Market

MARKET SUMMARY
-
4.50%
  • Study Period– 2022-2028
  • Base Year– 2021
  • CAGR– 4.50%
  • Largest Market– North American
  • Fastest Growing Market– Asia-Pacific

Hidradenitis Suppurativa Treatment Market

  • The hidradenitis suppurativa treatment market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • The hidradenitis suppurativa treatment market is segmented based on clinical stage, drug type, distribution channel and geography.
Key Players
  • AbbVie Inc.
  • AstraZeneca plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Allergan plc
Hidradenitis Suppurativa Treatment Market Drivers

Number of cases of various skin conditions has increased, and the FDA is approving more drugs and clinical trials are burgeon the market growth over the forecast years.


North America Got Significant Share

Hidradenitis Suppurativa Treatment Market

North America is expected to witness the highest market share during the forecast period due to factors like rising incidence of skin diseases and associated medical consequences, North America currently maintains the dominant market share.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The Hidradenitis suppurativa treatment market provides granular level information about the market size, regional market share, historic market (2017-2021) and forecast (2022-2028)
  • The Hidradenitis suppurativa treatment market covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The Hidradenitis suppurativa treatment market outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The Hidradenitis suppurativa treatment market tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The Hidradenitis suppurativa treatment market provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Hidradenitis Suppurativa Treatment Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The global Hidradenitis Suppurativa Treatment market size is valued at USD 721.9 million in 2021 and is expected to grow at a prominent growth rate during the forecast period 2022 to 2028.

 

 

 

.

High treatment costs, drug resistance, and unmet medical needs are some of the main obstacles thought to significantly impede the expansion of the hidradenitis suppurativa industry.

AstraZeneca (UK), Pfizer Inc.(US), GlaxoSmithKline plc. (UK), Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US)


Report

Table Of Content

1. Executive Summary
2. Global Hidradenitis Suppurativa Treatment Market Introduction
2.1. Global Hidradenitis Suppurativa Treatment Market – Taxonomy
2.2. Global Hidradenitis Suppurativa Treatment Market –Definitions
2.2.1. Clinical Stage
2.2.2. Drug Type
2.2.3. Distribution Channel
3. Global Hidradenitis Suppurativa Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Hidradenitis Suppurativa Treatment Market Dynamic Factors – Impact Analysis
3.6. Global Hidradenitis Suppurativa Treatment Market – Competition Landscape
4. Global Hidradenitis Suppurativa Treatment Market Analysis,2017-2021 and Forecast, 2022-2028
4.1. Market Analysis,2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Hidradenitis Suppurativa Treatment Market, By Clinical Stage, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.1. Hurley Stage 1
5.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Hurley Stage 2
5.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Hurley Stage 3
5.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
6. Global Hidradenitis Suppurativa Treatment Market Forecast, By Drug Type, 2017-2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1. Biologics
6.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Antibiotics
6.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Hormonal therapy
6.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Immune suppurativa drugs
6.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Pain medications
6.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Others
6.6.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
7. Global Hidradenitis Suppurativa Treatment Market, By Distribution Channel, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
7.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. Global Hidradenitis Suppurativa Treatment Market Forecast, By Region, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.1. North America
8.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Hidradenitis Suppurativa Treatment Market – Opportunity Analysis Index, By Clinical Stage, Drug Type, Distribution Channel and Region, 2022-2028
9. North America Hidradenitis Suppurativa Treatment MarketAnalysis,2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
9.1. By Clinical Stage Analysis 2017-2021 and Forecast 2022-2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
9.1.1. Hurley Stage 1
9.1.2. Hurley Stage 2
9.1.3. Hurley Stage 3
9.2. Drug Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Biologics
9.2.2. Antibiotics
9.2.3. Hormonal therapy
9.2.4. Immune suppurativa drugs
9.2.5. Pain medications
9.2.6. Others
9.3. Distribution Channel Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Country Analysis 2017-2021 and Forecast 2022-2028by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. USA
9.4.2. Canada
9.5. North America Hidradenitis Suppurativa Treatment Market – Opportunity Analysis Index, By Clinical Stage, Drug Type, Distribution Channel, and Country, 2022-2028
9.6. North America Hidradenitis Suppurativa Treatment Market Dynamics – Trends
10. Europe Hidradenitis Suppurativa Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
10.1. By Clinical Stage Analysis 2017-2021 and Forecast 2022-2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
10.1.1. Hurley Stage 1
10.1.2. Hurley Stage 2
10.1.3. Hurley Stage 3
10.2. Drug Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Biologics
10.2.2. Antibiotics
10.2.3. Hormonal therapy
10.2.4. Immune suppurativa drugs
10.2.5. Pain medications
10.2.6. Others
10.3. Distribution Channel Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Hidradenitis Suppurativa Treatment Market – Opportunity Analysis Index, By Clinical Stage, Drug Type, Distribution Channel, and Country, 2022-2028
10.6. Europe Hidradenitis Suppurativa Treatment Market Dynamics – Trends
11. Asia-Pacific Hidradenitis Suppurativa Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
11.1. By Clinical Stage Analysis 2017-2021 and Forecast 2022-2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
11.1.1. Hurley Stage 1
11.1.2. Hurley Stage 2
11.1.3. Hurley Stage 3
11.2. Drug Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Biologics
11.2.2. Antibiotics
11.2.3. Hormonal therapy
11.2.4. Immune suppurativa drugs
11.2.5. Pain medications
11.2.6. Others
11.3. Distribution Channel Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Country Analysis2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Hidradenitis Suppurativa Treatment Market – Opportunity Analysis Index, By Clinical Stage, Drug Type, Distribution Channel, and Country, 2022-2028
11.6. Asia-Pacific Hidradenitis Suppurativa Treatment Market Dynamics – Trends
12. Latin America Hidradenitis Suppurativa Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
12.1. By Clinical Stage Analysis 2017-2021 and Forecast 2022-2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
12.1.1. Hurley Stage 1
12.1.2. Hurley Stage 2
12.1.3. Hurley Stage 3
12.2. Drug Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Biologics
12.2.2. Antibiotics
12.2.3. Hormonal therapy
12.2.4. Immune suppurativa drugs
12.2.5. Pain medications
12.2.6. Others
12.3. Distribution Channel Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Rest of Latin America
12.5. Latin America Hidradenitis Suppurativa Treatment Market – Opportunity Analysis Index, By Clinical Stage, Drug Type, Distribution Channel, and Country, 2022-2028
12.6. Latin America Hidradenitis Suppurativa Treatment Market Dynamics – Trends
13. Middle East and Africa Hidradenitis Suppurativa Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
13.1. By Clinical Stage Analysis 2017-2021 and Forecast 2022-2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
13.1.1. Hurley Stage 1
13.1.2. Hurley Stage 2
13.1.3. Hurley Stage 3
13.2. Drug Type Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Biologics
13.2.2. Antibiotics
13.2.3. Hormonal therapy
13.2.4. Immune suppurativa drugs
13.2.5. Pain medications
13.2.6. Others
13.3. Distribution Channel Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Hidradenitis Suppurativa Treatment Market – Opportunity Analysis Index, By Clinical Stage, Drug Type, Distribution Channel, and Country, 2022-2028
13.6. MEA Hidradenitis Suppurativa Treatment Market Dynamics – Trends
14. Competition Landscape 
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Drug Type& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. AbbVie Inc.
14.2.2. AstraZeneca plc
14.2.3. Johnson & Johnson
14.2.4. Merck & Co., Inc.
14.2.5. Allergan plc
14.2.6. Pfizer Inc.
14.2.7. GlaxoSmithKline plc
14.2.8. LEO Pharma A/S
14.2.9. Novartis AG
14.2.10. AstraZeneca
15. Research Methodology
16. Key Assumptions and Acronyms

Report

Company Profile

  • AbbVie Inc.
  • AstraZeneca plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Allergan plc
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • LEO Pharma A/S
  • Novartis AG

Description

Hidradenitis Suppurativa Treatment Market size is valued at USD 721.9 million in 2021 and is expected to grow at a prominent growth rate 4.50% during the forecast period 2022 to 2028. The global market provides a detailed overview of the global Hidradenitis Suppurativa Treatment market, and that can be segmented by Clinical Stage, by Drug Type, by Distribution Channel. By Clinical Stage, the global Hidradenitis Suppurativa Treatment market has been segmented into Hurley Stage 1, Hurley Stage 2, Hurley Stage 3. The hurley stage 1 Suppurativa Treatment segment is likely to be the largest and fastest-growing segment in terms of type. Based on Drug type, the global Hidradenitis Suppurativa Treatment market is segmented into Biologics, Antibiotics, Hormonal therapy, Immune suppurativa drugs, Pain medications, Others. Among these, the biologics segment is expected to have the fastest-growing market during the forecast period 2022-2028. Based on distribution channel, the global Hidradenitis Suppurativa Treatment market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies. The Hospital Pharmacies segment accounts for the largest share in 2021. Retail segment is the second-largest share during the forecast period 2022-2028.

Key Developments:

In Feb 2019, InflaRx N.V., which is recognized for creating novel therapies to treat inflammatory diseases, recently released new clinical results including the use of IFX-1 in patients with moderate to severe Hidradenitis Suppurativa.

In March 2022, MoonLake began testing nanobody, sonelokimab in a Phase II clinical trial to treat moderate-to-severe hidradenitis suppurativa (HS). By blocking the IL-17A/A, IL-17A/F, and IL-17F/F dimers that induce inflammation in the body, sonelokimab may be able to cure inflammatory conditions.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX